Ar­rakis Ther­a­peu­tics re­duces head­count by 20%

Ar­rakis Ther­a­peu­tics has pri­or­i­tized its pipeline and re­duced its head­count by about 20% this week, the biotech’s CEO said in a state­ment to End­points News.

“We con­duct­ed a thor­ough re­view of our pipeline and have pri­or­i­tized pro­grams and ac­tiv­i­ties that we’re most ex­cit­ed about and pro­vide us with the clear­est path to de­liv­er­ing RNA-tar­get­ed small mol­e­cule med­i­cines to pa­tients,” CEO Michael Gilman wrote in an emailed state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER